Investigating the Time-Dependent Reversibility of DCM-Induced Epigenetic, Matrix, and Functional Remodeling
研究 DCM 诱导的表观遗传、基质和功能重塑的时间依赖性可逆性
基本信息
- 批准号:10812314
- 负责人:
- 金额:$ 4.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-16 至 2025-09-15
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAftercareAgeAge MonthsCardiacCardiologyCardiovascular DiseasesCardiovascular systemCellsChromatinCollagenCongestive Heart FailureCoupledCytoskeletonDNA MethylationDataDepositionDilated CardiomyopathyDiseaseDisease ProgressionDoseDoxycyclineEFRACEngineeringEnsureEpigenetic ProcessEtiologyExtracellular MatrixFamily suidaeFellowshipFibroblastsFibrosisFunctional disorderFutureGene ExpressionGenerationsGenesGenetic TranscriptionGenomeGenomicsGoalsHeartHeart DiseasesHeart HypertrophyHeart failureHumanHypertrophyIn VitroInduced MutationInheritedInjuryLearningLeft ventricular structureLinkMechanicsMedicineMemoryMentorsMentorshipMesenchymal Stem CellsMicrofilamentsModelingMusMuscle CellsMutateMutationMyocardial dysfunctionMyocardiumMyosin ATPaseNatureOrganOutcomePatientsPeriodicityPharmacological TreatmentPhenotypePhysiciansPoint MutationProgressive DiseaseProteomicsRepressionResearchResolutionRunningScientistSignal TransductionStructureSymptomsTechnologyTestingTherapeuticTimeTrainingTransgenic MiceTreatment FailureTroponin CUnited States National Institutes of Healthcareercareer developmentchromatin remodelingclinically relevanteffective therapyepigenetic memoryepigenomeexperimental studyfamilial dilated cardiomyopathyhealingheart functionimprovedinhibitormechanical stimulusmouse modelmultiple omicsmutantpalliativepatient variabilitypharmacologicpre-doctoralpressureprofessorresponsescreeningskillstherapeutic targettooltranscriptome sequencingtransgene expressiontranslational therapeutics
项目摘要
Project Summary
Dilated cardiomyopathy (DCM) is a highly prevalent inherited cardiac disease, characterized by systolic
dysfunction, eccentric hypertrophy, and left ventricle dilation. While pharmacologic and mechanical treatments
have been shown to partially improve cardiac function, these results are often short lived and highly variable
from patient to patient. Moreover, recent studies have demonstrated that epigenetic and matrix dysregulation
can persist, even in patients with improved systolic function after treatment. Given that aberrant chromatin
remodeling and extracellular matrix (ECM) deposition have been identified as drivers of dilated remodeling—and
that chromatin and ECM remodeling can become irreversible over time—it is crucial to understand the time-
dependent effects of DCM mutations on reversing maladaptive remodeling at the genome, myocyte, and matrix
levels. The central hypothesis of this proposal is that the reversibility of the DCM phenotype is time-dependent
due to the accumulation of permanent ECM and chromatin remodeling as the disease progresses. To complete
this proposal, I will utilize a DCM mouse model created by the Davis lab which contains a mutation (I61Q) in
cardiac troponin C (cTnC) that directly decreases the myofilament’s Ca2+ sensitivity, leading to eccentric
hypertrophy, systolic dysfunction, and left ventricle dilation. Importantly, expression of this mutant can be
temporally controlled with doxycycline to specifically test our central hypothesis. In this proposal I will 1)
Determine the time-dependent effects of I61Q cTnC expression on myocyte, matrix, and chromatin accessibility,
2) Examine the reversibility of DCM remodeling in myocyte, matrix, and chromatin accessibility at different stages
of the disease, and 3) Determine if myocytes retain epigenetic memories of the mechanical disequilibrium caused
by DCM. Improving our understanding of the time-dependent reversibility of DCM remodeling will better inform
therapeutic targets and treatment windows for patients with DCM. Moreover, completion of this project will
enhance Bella’s training as an independent scientist and prepare her to one day become a professor in
cardiovascular engineering. Receiving the NIH F31 predoctoral fellowship will facilitate important experiments
and training that will aid in her pursuit of this career goal. In this project, Bella will gain expertise in multi-omic
approaches—such as proteomics, RNAseq, and ATACseq—which are growing in popularity due to their
unbiased screening capabilities. The UW Genomics Core will assist Bella in learning how to effectively use these
tools, which will not only benefit this project but will also be an incredibly useful skillset for Bella’s future career.
Given the clinical relevance of this project, we have engaged Farid Moussavi-Harami, MD, an acting physician-
scientist who practices cardiology within the UW Department of Medicine. Dr. Moussavi-Harami’s input as a
clinician will be crucial for ensuring our research questions and aims remain relevant to patients, and his
mentorship throughout this project will enhance Bella’s training and career development as she aims to
eventually run a lab with an emphasis in translational therapeutics and technologies for cardiovascular diseases.
项目概要
扩张型心肌病(DCM)是一种高度流行的遗传性心脏病,其特征是收缩性心肌病
药物和机械治疗时出现功能障碍、离心性肥大和左心室扩张。
已被证明可以部分改善心脏功能,但这些结果通常是短暂的且变化很大
此外,最近的研究表明表观遗传和基质失调。
即使在治疗后收缩功能有所改善的患者中,由于染色质异常,这种情况也可能持续存在。
重塑和细胞外基质 (ECM) 沉积已被确定为扩张重塑的驱动因素,并且
随着时间的推移,染色质和 ECM 重塑可能变得不可逆转——了解时间至关重要——
DCM 突变对逆转基因组、肌细胞和基质的适应不良重塑的依赖性影响
该提议的中心假设是 DCM 表型的可逆性是时间依赖性的。
随着疾病的进展,永久性 ECM 的积累和染色质重塑得以完成。
在这个提案中,我将利用 Davis 实验室创建的 DCM 小鼠模型,其中包含一个突变 (I61Q)
心肌肌钙蛋白 C (cTnC) 直接降低肌丝的 Ca2+ 敏感性,导致离心
重要的是,该突变体的表达可以导致肥大、收缩功能障碍和左心室扩张。
用多西环素暂时控制,以具体测试我们的中心假设,在这个提案中,我将1)。
确定 I61Q cTnC 表达对肌细胞、基质和染色质可及性的时间依赖性影响,
2) 检查不同阶段DCM重塑的肌细胞、基质和染色质可及性的可逆性
3) 确定肌细胞是否保留了引起的机械不平衡的表观遗传记忆
提高我们对 DCM 重塑的时间依赖性可逆性的理解将更好地提供信息。
此外,该项目的完成将有助于 DCM 患者的治疗目标和治疗窗口。
加强贝拉作为一名独立科学家的培训,并为她有一天成为一名教授做好准备
获得 NIH F31 博士前奖学金将促进重要的实验。
以及有助于她实现这一职业目标的培训 在这个项目中,贝拉将获得多组学方面的专业知识。
蛋白质组学、RNAseq 和 ATACseq 等方法由于其优点而越来越受欢迎
华盛顿大学基因组学核心将帮助贝拉学习如何有效地使用这些能力。
工具,这不仅有利于这个项目,而且对贝拉未来的职业生涯来说也是非常有用的技能。
鉴于该项目的临床相关性,我们聘请了代理医师 Farid Moussavi-Harami 医学博士 -
Moussavi-Harami 博士是威斯康星大学医学系从事心脏病学工作的科学家。
临床医生对于我们的研究问题至关重要,其目标是与患者保持相关性,并确保他的研究成果
整个项目将加强贝拉的培训和职业发展,因为她的导师旨在
最终经营了一个实验室,重点研究心血管疾病的转化疗法和技术。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Isabella Reichardt其他文献
Isabella Reichardt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Isabella Reichardt', 18)}}的其他基金
Investigating the Time-Dependent Reversibility of DCM-Induced Epigenetic, Matrix, and Functional Remodeling
研究 DCM 诱导的表观遗传、基质和功能重塑的时间依赖性可逆性
- 批准号:
10535260 - 财政年份:2022
- 资助金额:
$ 4.26万 - 项目类别:
相似海外基金
Randomized Control Trial of Nitazoxanide for the Treatment of Cryptosporidium Infection in Malnourished Children in Bangladesh
硝唑尼特治疗孟加拉国营养不良儿童隐孢子虫感染的随机对照试验
- 批准号:
10551559 - 财政年份:2023
- 资助金额:
$ 4.26万 - 项目类别:
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 4.26万 - 项目类别:
Engineered tissue arrays to streamline deimmunized DMD gene therapy vectors
工程组织阵列可简化去免疫 DMD 基因治疗载体
- 批准号:
10724882 - 财政年份:2023
- 资助金额:
$ 4.26万 - 项目类别:
Uncertainty aware virtual treatment planning for peripheral pulmonary artery stenosis
外周肺动脉狭窄的不确定性虚拟治疗计划
- 批准号:
10734008 - 财政年份:2023
- 资助金额:
$ 4.26万 - 项目类别:
Enhancing Hypnotic Medication Discontinuation in Primary Care through Supervised Medication Tapering and Digital Cognitive Behavioral Insomnia Therapy
通过监督药物逐渐减量和数字认知行为失眠治疗,加强初级保健中催眠药物的停药
- 批准号:
10736443 - 财政年份:2023
- 资助金额:
$ 4.26万 - 项目类别: